Infectious Diseases R&D, Quest Diagnostics, San Juan Capistrano, CA, United States.
Front Cell Infect Microbiol. 2022 May 10;12:894613. doi: 10.3389/fcimb.2022.894613. eCollection 2022.
Genomic surveillance efforts for SARS-CoV-2 are needed to understand the epidemiology of the COVID-19 pandemic. Viral variants may impact routine diagnostic testing, increase viral transmissibility, cause differences in disease severity, have decreased susceptibility to therapeutics, and/or confer the ability to evade host immunity. While viral whole-genome sequencing (WGS) has played a leading role in surveillance programs, many laboratories lack the expertise and resources for performing WGS. This study describes the performance of multiplexed real-time reverse transcription-PCR (RT-PCR) assays for identification of SARS-CoV-2 variants.
SARS-CoV-2 specimens were tested for spike-gene variants using a combination of allele-specific primer and allele-specific detection technology (PlexPrime and PlexZyme). Targeted detection of spike gene mutations by RT-PCR was compared to variant detection in positive specimens by WGS, including the recently emerged SARS-CoV-2 Omicron variant.
A total of 398 SAR-CoV-2 RT-PCR positive and 39 negative specimens previously tested by WGS were re-tested by RT-PCR genotyping. PCR detection of spike gene mutations N501Y, E484K, and S982A correlated 100% with WGS for the 29 lineages represented, including Alpha (B.1.1.7), Beta (B.1.351), and Gamma (P.1). Incorporating the P681R spike gene mutation also allowed screening for the SARS-CoV-2 Delta variant (B.1.617.2 and AY sublineages). Further sampling of 664 specimens that were screened by WGS between June and August 2021 and then re-tested by RT-PCR showed strong agreement for Delta variant positivity: 34.5% for WGS vs 32.9% for RT-PCR in June; 100% vs 97.8% in August. In a blinded panel of 16 Omicron and 16 Delta specimens, results of RT-PCR were 100% concordant with WGS results.
These data demonstrate that multiplexed real-time RT-PCR genotyping has strong agreement with WGS and may provide additional SARS-CoV-2 variant screening capabilities when WGS is unavailable or cost-prohibitive. RT-PCR genotyping assays may also supplement existing sequencing efforts while providing rapid results at or near the time of diagnosis to help guide patient management.
需要对 SARS-CoV-2 进行基因组监测,以了解 COVID-19 大流行的流行病学情况。病毒变异可能会影响常规诊断检测,增加病毒的传染性,导致疾病严重程度的差异,降低对治疗药物的敏感性,以及/或赋予逃避宿主免疫的能力。虽然病毒全基因组测序(WGS)在监测计划中发挥了主导作用,但许多实验室缺乏进行 WGS 的专业知识和资源。本研究描述了用于鉴定 SARS-CoV-2 变体的多重实时逆转录-PCR(RT-PCR)检测方法的性能。
使用等位基因特异性引物和等位基因特异性检测技术(PlexPrime 和 PlexZyme)对尖峰基因变异体进行 SARS-CoV-2 标本检测。通过 WGS 对阳性标本中的尖峰基因突变进行靶向检测,并与 RT-PCR 检测进行比较,包括最近出现的 SARS-CoV-2 奥密克戎变异体。
共对 398 份以前通过 WGS 检测为 SAR-CoV-2 RT-PCR 阳性和 39 份阴性标本进行了 RT-PCR 基因分型再检测。PCR 检测尖峰基因 N501Y、E484K 和 S982A 的突变与 WGS 检测的 29 个谱系(包括 Alpha(B.1.1.7)、Beta(B.1.351)和 Gamma(P.1))完全一致。纳入尖峰基因 P681R 突变也可以筛查 SARS-CoV-2 Delta 变体(B.1.617.2 和 AY 亚谱系)。进一步对 2021 年 6 月至 8 月间通过 WGS 筛查的 664 份标本进行了采样,并通过 RT-PCR 进行了再检测,结果显示 Delta 变体阳性的一致性较强:6 月时 WGS 为 34.5%,RT-PCR 为 32.9%;8 月时为 100%和 97.8%。在 16 份奥密克戎和 16 份德尔塔标本的盲法检测中,RT-PCR 的结果与 WGS 结果完全一致。
这些数据表明,多重实时 RT-PCR 基因分型与 WGS 具有很强的一致性,在 WGS 不可用或成本过高时,可能提供额外的 SARS-CoV-2 变体筛选能力。RT-PCR 基因分型检测还可以补充现有的测序工作,同时在诊断时或接近诊断时提供快速结果,以帮助指导患者管理。